The Prognostic Value of the Clinical Frailty Scale Without Category 9 in Older Adults with Advanced Cancer.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42576425.
- Also identified by DOI 10.1177/10966218261476769.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Clinical Frailty Scale (CFS) is widely used, but the "terminally ill" category 9-defined by <i>a</i> <6-month prognosis-may limit nuanced survival estimation in geriatric oncology. To evaluate the prognostic utility of the CFS when category 9 is omitted. This retrospective study analyzed 901 older adults (≥65 years) with incurable cancer at a palliative clinic. Patients were stratified into CFS 2-5 (<i>n</i> = 618) and CFS 6-8 (<i>n</i> = 283). Survival was assessed using multivariate Cox regression. Median survival was significantly shorter for CFS 6-8 compared to CFS 2-5 (90 vs. 158 days; <i>p</i> < 0.001). For 3-month mortality, CFS 6-8 demonstrated a hazard ratio (HR) of 2.25 compared to CFS 2-5. After adjusting for age, symptoms, albumin, and comorbidities, the CFS remained an independent predictor of 3-month (HR 2.07) and 6-month mortality (HR 1.57). Omitting category 9 allows the CFS to provide meaningful prognostic data, facilitating better end-of-life planning in geriatric oncology.